BioSpace News Archive

XOMA Corporation announced it has acquired an economic interest in DSUVIA® from Talphera, Inc., for $8 million.

Surrozen, Inc. announced that enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete.

Adial Pharmaceuticals, Inc. today announced the appointment of Tony Goodman as Chief Operating Officer.

TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA ® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis (gMG).

Elevar Therapeutics, Inc. today announced it will present two posters and give an Industry Expert Theater presentation at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”) today announced that Adam Levy, Chief Executive Officer, will be participating in The Microcap Conference, which will take place January 30th through February 1st at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients.

Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.

ALK (ALKB:DC / OMX: ALK B / AKBLF) announced today that it has completed the first part of its phase 1 clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy.